Comprehensive Review of Neuromyelitis Optica and Clinical Characteristics of Neuromyelitis Optica Patients in Puerto Rico

Overview

Journal Surg Neurol Int

Specialty Neurology

Date 2019 Jan 4

PMID 30603227

Citations 9

Authors

Sara Zarei

James Eggert

Laura Franqui-Dominguez

Yonatan Carl

Fernando Boria

Marina Stukova

Alessandro Avila

Cristina Rubi

Angel Chinea

Affiliations

Soon will be listed here.

Abstract

Neuromyelitis optica (NMO) is an immune-mediated inflammatory disorder of the central nervous system. It is characterized by concurrent inflammation and demyelination of the optic nerve (optic neuritis [ON]) and the spinal cord (myelitis). Multiple studies show variations in prevalence, clinical, and demographic features of NMO among different populations. In addition, ethnicity and race are known as important factors on disease phenotype and clinical outcomes. There are little data on information about NMO patients in underserved groups, including Puerto Rico (PR). In this research, we will provide a comprehensive overview of all aspects of NMO, including epidemiology, environmental risk factors, genetic factors, molecular mechanism, symptoms, comorbidities and clinical differentiation, diagnosis, treatment, its management, and prognosis. We will also evaluate the demographic features and clinical phenotype of NMO patients in PR. This will provide a better understanding of NMO and establish a basis of knowledge that can be used to improve care. Furthermore, this type of population-based study can distinguish the clinical features variation among NMO patients and will provide insight into the potential mechanisms that cause these variations.

Citing Articles

Genetic Basis of Inflammatory Demyelinating Diseases of the Central Nervous System: Multiple Sclerosis and Neuromyelitis Optica Spectrum.

Ortiz G, Torres-Mendoza B, Ramirez-Jirano J, Marquez-Pedroza J, Hernandez-Cruz J, Mireles-Ramirez M Genes (Basel). 2023; 14(7).

PMID: 37510224 PMC: 10379341. DOI: 10.3390/genes14071319.

The preventive Effectiveness of Rituximab in Pediatric Autoimmune and Inflammatory CNS Diseases Relapse: an Iranian Experience.

Nasehi M, Ghofrani M, Tabrizi A, Abdollah Gorji F, Khosravi B Iran J Child Neurol. 2022; 16(3):167-182.

PMID: 36204433 PMC: 9531201. DOI: 10.22037/ijcn.v16i3.29322.

Identification of Novel Serum Proteins Associated with Myelination and Cholesterol Transport in Neuromyelitis Optica Spectrum Disorders by Mass Spectrometry.

John M, Maria E, Das S, T H Indian J Clin Biochem. 2022; 37(3):275-284.

PMID: 35873620 PMC: 9300782. DOI: 10.1007/s12291-021-01004-w.

A CD33 frameshift variant is associated with neuromyelitis optica spectrum disorders.

Huang Y, Lee J, Fan W, Hsu C, Tsai N, Lu C Biomed J. 2022; 44(6 Suppl 1):S93-S100.

PMID: 35735085 PMC: 9038945. DOI: 10.1016/j.bj.2020.07.007.

A Rare Case of Neuromyelitis Optica Spectrum Disorders With Unknown Fever and Subacute Cognitive Decline With Normal Images.

Furuya K, Itoh N Cureus. 2022; 14(5):e24950.

PMID: 35698698 PMC: 9188466. DOI: 10.7759/cureus.24950.

References

Popescu B, Lennon V, Parisi J, Howe C, Weigand S, Cabrera-Gomez J . Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications. Neurology. 2011; 76(14):1229-37. PMC: 3068006. DOI: 10.1212/WNL.0b013e318214332c. View

Wang H, Zhong X, Wang K, Qiu W, Li J, Dai Y . Interleukin 17 gene polymorphism is associated with anti-aquaporin 4 antibody-positive neuromyelitis optica in the Southern Han Chinese--a case control study. J Neurol Sci. 2011; 314(1-2):26-8. DOI: 10.1016/j.jns.2011.11.005. View

Wang J, Tian Y, Shao Y, Feng H, Qin L, Xu W . Comparison of spontaneous brain activity revealed by regional homogeneity in AQP4-IgG neuromyelitis optica-optic neuritis versus MOG-IgG optic neuritis patients: a resting-state functional MRI study. Neuropsychiatr Dis Treat. 2017; 13:2669-2679. PMC: 5661477. DOI: 10.2147/NDT.S145183. View

Johnson B, Fram E, Johnson P, JACOBOWITZ R . The variable MR appearance of primary lymphoma of the central nervous system: comparison with histopathologic features. AJNR Am J Neuroradiol. 1997; 18(3):563-72. PMC: 8338430. View

Sahraian M, Naser Moghadasi A, Azimi A, Asgari N, Akhoundi F, Abolfazli R . Diagnosis and management of Neuromyelitis Optica Spectrum Disorder (NMOSD) in Iran: A consensus guideline and recommendations. Mult Scler Relat Disord. 2017; 18:144-151. DOI: 10.1016/j.msard.2017.09.015. View

Cantorna M, Mahon B . Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence. Exp Biol Med (Maywood). 2004; 229(11):1136-42. DOI: 10.1177/153537020422901108. View

Shan Y, Tan S, Zhang L, Huang J, Sun X, Wang Y . Serum 25-hydroxyvitamin D is associated with disease status in patients with neuromyelitis optica spectrum disorders in south China. J Neuroimmunol. 2016; 299:118-123. DOI: 10.1016/j.jneuroim.2016.09.006. View

Rybicki B, Major M, Popovich Jr J, Maliarik M, Iannuzzi M . Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol. 1997; 145(3):234-41. DOI: 10.1093/oxfordjournals.aje.a009096. View

Kim S, Woodhall M, Kim J, Kim S, Park K, Vincent A . Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS. Neurol Neuroimmunol Neuroinflamm. 2015; 2(6):e163. PMC: 4608758. DOI: 10.1212/NXI.0000000000000163. View

10.

Araki M, Matsuoka T, Miyamoto K, Kusunoki S, Okamoto T, Murata M . Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study. Neurology. 2014; 82(15):1302-6. PMC: 4001188. DOI: 10.1212/WNL.0000000000000317. View

11.

Flanagan E, Kaufmann T, Krecke K, Aksamit A, Pittock S, Keegan B . Discriminating long myelitis of neuromyelitis optica from sarcoidosis. Ann Neurol. 2015; 79(3):437-47. DOI: 10.1002/ana.24582. View

12.

Jarius S, Paul F, Franciotta D, De Seze J, Munch C, Salvetti M . Neuromyelitis optica spectrum disorders in patients with myasthenia gravis: ten new aquaporin-4 antibody positive cases and a review of the literature. Mult Scler. 2011; 18(8):1135-43. DOI: 10.1177/1352458511431728. View

13.

Jellema K, Canta L, Tijssen C, van Rooij W, Koudstaal P, van Gijn J . Spinal dural arteriovenous fistulas: clinical features in 80 patients. J Neurol Neurosurg Psychiatry. 2003; 74(10):1438-40. PMC: 1757384. DOI: 10.1136/jnnp.74.10.1438. View

14.

Michel M, Barendrecht M . Physiological and pathological regulation of the autonomic control of urinary bladder contractility. Pharmacol Ther. 2008; 117(3):297-312. DOI: 10.1016/j.pharmthera.2007.12.001. View

15.

Fu Q, Goodrum J, Hayes C, Hostettler J, Toews A, Morell P . Control of cholesterol biosynthesis in Schwann cells. J Neurochem. 1998; 71(2):549-55. DOI: 10.1046/j.1471-4159.1998.71020549.x. View

16.

Koelman D, Chahin S, Mar S, Venkatesan A, Hoganson G, Yeshokumar A . Acute disseminated encephalomyelitis in 228 patients: A retrospective, multicenter US study. Neurology. 2016; 86(22):2085-93. DOI: 10.1212/WNL.0000000000002723. View

17.

Cha E, Lee K, Park K, Park K, Lee K, Kim S . Hydroxycholesterol Levels in the Serum and Cerebrospinal Fluid of Patients with Neuromyelitis Optica Revealed by LC-Ag+CIS/MS/MS and LC-ESI/MS/MS with Picolinic Derivatization: Increased Levels and Association with Disability during Acute Attack. PLoS One. 2016; 11(12):e0167819. PMC: 5152860. DOI: 10.1371/journal.pone.0167819. View

18.

Pisani F, Mastrototaro M, Rossi A, Nicchia G, Tortorella C, Ruggieri M . Identification of two major conformational aquaporin-4 epitopes for neuromyelitis optica autoantibody binding. J Biol Chem. 2011; 286(11):9216-24. PMC: 3059066. DOI: 10.1074/jbc.M110.123000. View

19.

Zajicek J, Scolding N, Foster O, Rovaris M, Evanson J, Moseley I . Central nervous system sarcoidosis--diagnosis and management. QJM. 1999; 92(2):103-17. DOI: 10.1093/qjmed/92.2.103. View

20.

Janowski B, Willy P, Devi T, Falck J, Mangelsdorf D . An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature. 1996; 383(6602):728-31. DOI: 10.1038/383728a0. View